This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / AIM ImmunoTech Rintatolimod...
Business clinical trial update

AIM ImmunoTech Rintatolimod Pancreatic Cancer Trial Milestones

Analysis based on 9 articles · First reported Feb 05, 2026 · Last updated Feb 23, 2026

Sentiment
60
Attention
4
Articles
9
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The announcement of positive milestones and an encouraging safety profile for AIM ImmunoTech===Rintatolimod in pancreatic cancer could significantly boost investor confidence in AIM ImmunoTech Inc., potentially leading to an increase in its stock price. The focus on pancreatic cancer and the potential for a Phase 3 trial could also attract larger biotech companies for mergers and acquisitions, impacting the broader pharmaceutical market.

Biotechnology Pharmaceuticals Healthcare
Event Summary

AIM ImmunoTech Inc. announced key milestones for its ongoing Phase 2 DURIPANC clinical study, evaluating AIM ImmunoTech===Rintatolimod combined with AstraZeneca's AstraZeneca===Durvalumab for metastatic pancreatic cancer. The study, a collaboration between AIM ImmunoTech Inc., AstraZeneca, and Erasmus MC, has enrolled 18 subjects. Planned milestones include completing subject enrollment by July 2026, full AIM ImmunoTech===Rintatolimod dosing by August 2026, and evaluation of the primary endpoint by December 2026. Lead investigator Marjolein Y. V. Homs reported promising Progression-Free Survival and Overall Survival, with no significant toxicity and high quality of life for AIM ImmunoTech===Rintatolimod subjects. AIM ImmunoTech Inc. is prioritizing AIM ImmunoTech===Rintatolimod's approval for pancreatic cancer, viewing it as a significant financial opportunity for stockholders.

Key Actions
100 AIM ImmunoTech announced milestones for clinical study
80 AIM ImmunoTech collaborated on clinical trial AstraZeneca
80 AIM ImmunoTech collaborated on clinical trial Erasmus MC
70 Erasmus MC conducted investigator-initiated study
60 Marjolein Y. V. Homs emphasized promising results and ongoing enrollment
Entities Involved
stock
AIM ImmunoTech
AIM ImmunoTech Inc. announced milestones for its Phase 2 clinical study of AIM ImmunoTech===Rintatolimod combined with AstraZeneca===Durvalumab for metastatic pancreatic cancer. The company is prioritizing AIM ImmunoTech===Rintatolimod's approval for pancreatic cancer, which could lead to significant financial potential for its stockholders through potential mergers and acquisitions.
Importance 100 Sentiment 70
subs
AIM ImmunoTech===Rintatolimod
AIM ImmunoTech===Rintatolimod (rintatolimod) is AIM ImmunoTech Inc.'s lead drug product, being evaluated in a Phase 2 clinical study for metastatic pancreatic cancer. Promising Progression-Free Survival and Overall Survival were seen in Phase 1, and no significant toxicity has been reported in Phase 2, with subjects reporting high quality of life.
Importance 90 Sentiment 70
stock
AstraZeneca
AstraZeneca is collaborating with AIM ImmunoTech Inc. and Erasmus MC on the DURIPANC study, contributing its anti-PD-L1 immune checkpoint inhibitor AstraZeneca===Durvalumab. The collaboration highlights AstraZeneca's involvement in advanced cancer research.
Importance 60 Sentiment 20
subs
AstraZeneca===Durvalumab
AstraZeneca===Durvalumab (durvalumab) is AstraZeneca's anti-PD-L1 immune checkpoint inhibitor being combined with AIM ImmunoTech===Rintatolimod in the DURIPANC study for metastatic pancreatic cancer. Its inclusion in the study is part of a joint collaboration.
Importance 60 Sentiment 20
ngo
Erasmus MC
Erasmus MC is a key collaborator and the single-center investigator for the DURIPANC study. They are responsible for conducting the clinical trial and have reported promising results and ongoing enrollment.
Importance 50 Sentiment 10
per
Marjolein Y. V. Homs
Marjolein Y. V. Homs, MD, PhD, from the Department of Medical Oncology at Erasmus MC Cancer Institute, is the lead investigator for the DURIPANC study. She emphasized the promising results and ongoing enrollment.
Importance 40 Sentiment 10
cnt
Netherlands
The Netherlands is the host nation for Erasmus MC, where the DURIPANC study is being conducted.
Importance 10 Sentiment 0
Relationships
AIM ImmunoTech related ↔ AstraZeneca
AIM ImmunoTech related ↔ Erasmus MC
AIM ImmunoTech===Rintatolimod related ↔ AIM ImmunoTech
AstraZeneca===Durvalumab related ↔ AstraZeneca
Marjolein Y. V. Homs related ↔ Erasmus MC
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.